National Cancer Institute - NCI Division of Cancer Treatment and ...

Dr. James H. Doroshow, Director
James H. Doroshow,
M.D., FACP, has been
the Director of the
Division of Cancer
Treatment and Diagnosis
(DCTD), National
Cancer Institute (NCI),
National Institutes
of Health (NIH), since
2004. He fosters collaboration with other NCI
divisions and offices, as well as extramural
scientists and clinicians, patient advocates,
and professional cancer organizations. He
leads the DCTD professional staff, who represent
a wide array of scientific specialties, to
integrate their insights and skills into a crossdisciplinary,
scientifically driven, cooperative
research endeavor to discover and develop
better diagnostic and therapeutic interventions
for cancer.
Dr. Doroshow also oversees his own active
laboratory program focusing on two lines of
research: discovering the mechanisms that
drive the anthracycline antibiotic cell death
program and understanding the role of
oxidative signals in the development and
treatment of colon cancer.
From 1983 to 2004, Dr. Doroshow was the
Associate Director for Clinical Research at the
City of Hope’s (COH) Comprehensive Cancer
Center in Duarte, California; the Chairman of
the COH Department of Medical Oncology
and Therapeutics Research; and the Leader of
the COH Cancer Center’s Clinical and Experimental
Therapeutics Program. Through these
roles, he oversaw solid tumor therapeutic
research, supervised a staff of 75 involved in
investigating novel targeted agents and other
therapies, and directed a program of clinical
research that supported more than 150 concurrently
active clinical trials. While at COH,
he founded an early therapeutics consortium
of three NCI-designated cancer centers in
California funded by both NCI’s phase I and
II support grants. He was also the principal
2 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6
investigator for COH’s membership in the
Southwest Oncology Group (SWOG) and
founding Chair of the SWOG Early
Therapeutics Committee.
From the time he received his first research
grant in 1980, Dr. Doroshow was funded continuously
by NCI and NIH until moving to NCI
in 2004. He is the author of more than 300
full-length publications in the areas of the
molecular and clinical pharmacology of the
anthracycline antibiotics, the role of oxidant
stress in signal transduction, and novel therapeutic
approaches to breast, gastrointestinal,
lung, and gynecologic cancer. Dr. Doroshow
is a senior editor of Clinical Cancer Research.
He is a member of the editorial boards of
International Journal of Oncology, Technology
in Cancer Research and Treatment, and
Oncology. He is also an associate editor for
the widely used Manual of Clinical Oncology
published by the International Union Against
Cancer. Dr. Doroshow served from 1995 to
2001 as a member of the Subspecialty Board
on Medical Oncology of the American Board
of Internal Medicine, from 1999 to 2000 as
Chair of NCI’s Scientific Review Group A-
Cancer Centers, and from 1990 to 1992 as
Chair of the NIH Experimental Therapeutics II
Study Section. He is currently a member
of the U.S. Food and Drug Administration
Oncologic Drugs Advisory Committee.
Dr. Doroshow received his bachelor’s degree,
magna cum laude, from Harvard College in
1969 and his medical degree, Alpha Omega
Alpha, from Harvard Medical School in 1973.
After completing an internship and residency
at Massachusetts General Hospital in Boston,
he spent three years (1975–1978) at NCI as
a clinical associate. He is board-certified in
internal medicine and medical oncology. Prior
to joining COH in 1981, he held the position
of Assistant Professor of Medicine in the
Division of Medical Oncology at the University
of Southern California School of Medicine
in Los Angeles.